Dopa-responsive dystonia: recent advances and remaining issues to be addressed
- PMID: 10495030
- DOI: 10.1002/1531-8257(199909)14:5<709::aid-mds1001>3.0.co;2-t
Dopa-responsive dystonia: recent advances and remaining issues to be addressed
Abstract
It is evident from this review that there is much that we know and much that we still do not know about DRD. In terms of diagnosis and clinical management, there is general agreement that patients with childhood-onset dystonic symptoms of unknown etiology should be treated initially with levodopa with the later addition, if necessary, of other medications (for example, BH4, 5-hydroxytryptophan). Although the results of molecular genetic and CSF studies are, at this time, unlikely to significantly alter clinical management of the patient, these analyses could be useful in providing information on prognosis (that is, DRD versus progressive neurodegenerative disorders or more severe metabolic disorders). It is also clear that notwithstanding the discovery of GCH1 and hTH mutations responsible for DRD, there remain many important unresolved issues regarding this disorder, including questions of female predominance, phenotypic heterogeneity, and presence of childhood-onset dystonia versus the expected parkinsonism resulting from a striatal DA deficit. We are confident that answers to these interesting questions on DRD will, in addition to providing clarification of the mechanisms of this disorder, provide exciting information relating to the pathogenesis of other types of dystonia as well as PD and to long-standing issues regarding a role of DA and serotonin in normal human brain development.
Similar articles
-
[Dopa-responsive dystonia: clinical, genetic, and biochemical studies].Rinsho Shinkeigaku. 2006 Jan;46(1):19-34. Rinsho Shinkeigaku. 2006. PMID: 16541791 Japanese.
-
Genetics and biochemistry of dopa-responsive dystonia: significance of striatal tyrosine hydroxylase protein loss.Adv Neurol. 2003;91:401-10. Adv Neurol. 2003. PMID: 12442699
-
Dopa-responsive dystonia and early-onset Parkinson's disease in a patient with GTP cyclohydrolase I deficiency?Mov Disord. 2006 May;21(5):679-82. doi: 10.1002/mds.20773. Mov Disord. 2006. PMID: 16267845
-
Molecular genetics of dopa-responsive dystonia.Biol Chem. 1999 Dec;380(12):1355-64. doi: 10.1515/BC.1999.175. Biol Chem. 1999. PMID: 10661862 Review.
-
Mutations of GCH1 in Dopa-responsive dystonia.J Neural Transm (Vienna). 2002 Mar;109(3):321-8. doi: 10.1007/s007020200026. J Neural Transm (Vienna). 2002. PMID: 11956954 Review.
Cited by
-
An Inversion Affecting the GCH1 Gene as a Novel Finding in Dopa-Responsive Dystonia.Mov Disord Clin Pract. 2024 May;11(5):582-585. doi: 10.1002/mdc3.14023. Epub 2024 Mar 18. Mov Disord Clin Pract. 2024. PMID: 38497520 Free PMC article. No abstract available.
-
Primary dystonia: molecules and mechanisms.Nat Rev Neurol. 2009 Nov;5(11):598-609. doi: 10.1038/nrneurol.2009.160. Epub 2009 Oct 13. Nat Rev Neurol. 2009. PMID: 19826400 Free PMC article. Review.
-
Parkinson's disease: genetics and beyond.Curr Neuropharmacol. 2007;5(2):99-113. doi: 10.2174/157015907780866893. Curr Neuropharmacol. 2007. PMID: 18615181 Free PMC article.
-
Genetic diagnosis of two dopa-responsive dystonia families by exome sequencing.PLoS One. 2014 Sep 2;9(9):e106388. doi: 10.1371/journal.pone.0106388. eCollection 2014. PLoS One. 2014. PMID: 25181484 Free PMC article.
-
Evaluation of Iterative Reconstruction Method and Attenuation Correction in Brain Dopamine Transporter SPECT Using an Anthropomorphic Striatal Phantom.Asia Ocean J Nucl Med Biol. 2016 Summer;4(2):72-80. doi: 10.7508/aojnmb.2016.02.003. Asia Ocean J Nucl Med Biol. 2016. PMID: 27408895 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical